Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7862638 | 0.83 | MEN1 (0.46) | ALDH1A1MAPTLMNATDP1MEN1 | |
| SCHEMBL16011491 | 0.83 | FFAR4 (0.40) | AMY1AFFAR4TAAR1TRPA1ALDH1A1 | |
| SCHEMBL30360666 | 0.83 | FFAR4 (0.40) | AMY1AFFAR4TAAR1TRPA1ALDH1A1 | |
| SCHEMBL29386482 | 0.82 | NPC1 (0.38) | AMY1ATRPA1ALDH1A1MAPTLMNA | |
| SCHEMBL1588133 | 0.82 | NPC1 (0.38) | AMY1ATRPA1ALDH1A1MAPTLMNA | |
| SCHEMBL30806439 | 0.79 | TAAR1 (0.39) | AMY1AFFAR4TAAR1TRPA1ALDH1A1 | |
| SCHEMBL4882598 | 0.79 | GABRA1 (0.41) | AMY1AFFAR4TAAR1ALDH1A1MAPT | |
| SCHEMBL2291344 | 0.79 | TAAR1 (0.39) | AMY1AFFAR4TAAR1TRPA1ALDH1A1 | |
| SCHEMBL233241 | 0.78 | AMY1A (0.43) | AMY1ATAAR1TRPA1ALDH1A1CYP1A2 | |
| SCHEMBL30150898 | 0.78 | AMY1A (0.43) | AMY1ATAAR1TRPA1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827616-B2 | Heterocyclic compounds as pesticides | DISCOVERY PURCHASER CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| EP-3862003-B1 | AN SGLT-2 INHIBITOR FOR USE IN THE TREATMENT OF A METABOLIC DISORDER IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-10-25 | — | — | EP | disclosed |
| EP-4245765-A2 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-4234012-A2 | SGLT2 INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-08-30 | — | — | EP | disclosed |
| EP-2981269-B1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-08-09 | — | — | EP | disclosed |
| EP-3485890-B1 | SGLT2 INHIBITORS FOR TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-4166548-A1 | CRYSTALLINE MONOHYDRATE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(BETA-D-GLUCOPYRANOS-1-YL)-BENZENE AND L-PROLINE IN CRYSTAL WATER (1:1:1) | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-04-19 | — | — | EP | disclosed |
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| WO-2021143924-A1 | BORIC ACID DERIVATIVE | 首药控股(北京)股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-3082829-B1 | SGLT2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8106031-B2 | Hydrolytically-resistant boron-containing therapeutics and methods of use | ANACOR PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2149560-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
| WO-2007128749-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | ANACOR PHARMACEUTICALS (US) | 2007-11-15 | — | — | US | disclosed |
| WO-2007093610-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZONITRILE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| US-3985889-A | 1,3-DIHYDROSPIRO(ISOBENZOFURAN); ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962259-A | TRANQUILIZERS, ANALGETIC AGENTS | AMERICAN HOECHST CORPORATION (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | AMY1A 2903/4885FFAR4 2333/4885TAAR1 3197/4885 |
| US-11827616-B2 | Heterocyclic compounds as pesticides | DDT, CHRM1, ACHE | AMY1A 427/4885FFAR4 3362/4885TAAR1 366/4885 |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | AMY1A 2776/4885FFAR4 1066/4885TAAR1 794/4885 |
| US-20070265226-A1 | Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use | GAA, BTD, MANBA | AMY1A 364/4885FFAR4 4427/4885TAAR1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.